Insulin in type 2 diabetes: Promises to keep

Journal of the Indian Medical Association

Volumn 102, Issue 8, 2004, Pages 438-444

  Basu, A K ^a   Bandyopadhyay, D ^a   Bandyopadhyay, R ^a   Majumdar, D ^a   Chakrabarty, P P ^a  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Diabetes; Insulin; Oral hypoglycaemic agents

Indexed keywords

C PEPTIDE; INTERLEUKIN 6; RECOMBINANT HUMAN INSULIN; TUMOR NECROSIS FACTOR ALPHA;

CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIABETES CONTROL; DIET RESTRICTION; GENETIC RISK; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

EID: 12344256750     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Berger M, Jorgens V, Mulhauser I - Rationale for the use of insulin therapy alone as the pharmacological treatemnt of type 2 diabetes. Diabetes Care 1999; 22: C71-C-75.
2. Alvarson M, Sundkvist G, Lager I, Henricsson M, Berntorp K. Fernqvist-Forbes E, et al - Beneficial effects of insulin versus sulphonylurea in insulin secretion and metabolic control in recently diagnosed type 2 diabetes mellitus patients. Diabetes Care 2003; 26: 2231-7.
3. Ponte CD - β-cells in type 2 diabetes. Diabetes 1991; 40: 166-80.
4. Iikova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E - Introduction of long term glycemic control in newly diagnosed type 2 DM by intensive insulin treatment. Diabetes Care 1997; 20: 1353-6.
5. Das UN - Insulin - an anti-inflammatory molecule. Nutrition 2001; 17: 409-13.
6. Rachman J, Levy JC, Barrow BA, Payne MJ, Turner RC, Holman RR - Changes in amylin and amylin-like peptide concentrations and β-cell function in response to sulphonylurea or insulin therapy in NIDDM. Diabetes Care 1998; 21: 810-6.
7. Kang S, Song J, Kang H, Kim S, Lee Y, Park D - Insulin can block apoptosis by decreasing oxidative stress via phoshatidylinositol 3-kinase- and extracellular signal-regulated protein kinase-dependent signaling pathways in HepG2 Cells. Eur J Endocrinol 2003; 148: 147-55.
8. Heise T, Sawicki PT - Does insulin preserve beta cell function in type 2 diabetes? J Int Med Res 2002; 251: 283-5.
9. Wright A, Burden ACF, Paisey RB for the UKPDS group - Sulphonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK prospective diabetes study. Diabetes Care 2002; 25: 330-6.
10. Peuchant E, Delmas-Beauvieux M, Couchouron A, Dubourg L, Thomas MJ, Perromat A, et al - Short-term insulin therapy and normoglycemia: effects on erythrocyte lipid peroxidation in NIDDM patients. Diabetes Care 1997; 20: 392-7.
11. Ryan EA, Imes S, Wallace C - Short term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-32.
12. Fariba SM, Powrie JK, Sundermann E, Spring MW, Schuttler A, Sonksen PH, et al - Novel hepatoselective insulin analogue. Diabetes Care 2000; 23: 1124-5.
13. Park S, Choi SB - Induction of long term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Rev 2003; 19: 124-30.
14. Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B - Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 2003; 20: 63-71.
15. Boidoui GB, Di'Marchi RD - Insulin analogues in type 2 diabetes. Diabetologia 1999; 42: 1151-67.
16. Nathan DM - Initial control of glycemia in type 2 DM. N Engl J Med 2002; 347: 1342-9.